Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747358 | 0.87 | — | — | |
| SCHEMBL6328723 | 0.87 | CTNNB1 (0.33) | CTNNB1WNT3APOLBNPSR1ALDH1A1 | |
| SCHEMBL6322793 | 0.74 | CTNNB1 (0.47) | CTNNB1WNT3AHDAC4FAAH | |
| SCHEMBL6320203 | 0.73 | RAB9A (0.37) | CTNNB1POLBNPSR1ALDH1A1HTT | |
| SCHEMBL7592861 | 0.73 | NPC1 (0.37) | POLBNPSR1ALDH1A1HTT | |
| SCHEMBL14337851 | 0.72 | CTNNB1 (0.33) | CTNNB1WNT3APOLBNPSR1KMT2A | |
| SCHEMBL14337914 | 0.70 | POLB (0.34) | POLBNPSR1KMT2AMEN1APOBEC3A | |
| SCHEMBL14338020 | 0.70 | POLB (0.34) | POLBNPSR1KMT2AMEN1APOBEC3A | |
| SCHEMBL14337973 | 0.70 | POLB (0.34) | POLBNPSR1KMT2AMEN1APOBEC3A | |
| SCHEMBL14337845 | 0.69 | KMT2A (0.38) | CTNNB1WNT3APOLBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878665-B2 | Diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | SYNKEM (FR) | 2005-04-12 | — | — | US | disclosed |
| US-20040260101-A1 | Novel diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | SYNKEM (FR) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260101-A1 | Novel diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | TPI1, TCP1, TTI2 | CTNNB1 594/4885WNT3A 658/4885POLB 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.